Connor, Clark & Lunn Investment Management (CC&L)’s Denali Therapeutics DNLI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-61,096	Closed	-$1.7M	–	1295
2022 Q4	$1.7M	Sell	61,096 -51,436	-46%	-$1.53M	0.01%	585
2022 Q3	$3.45M	Buy	+112,532	New	+$3.66M	0.02%	394
2021 Q3	–	Sell	-19,993	Closed	-$1.57M	–	1088
2021 Q2	$1.57M	Sell	19,993 -17,913	-47%	-$1.11M	0.01%	594
2021 Q1	$2.16M	Buy	37,906 +18,229	+93%	+$1.22M	0.01%	545
2020 Q4	$1.65M	Buy	+19,677	New	+$1.19M	0.01%	544

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s DNLI Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 61,096 shares — an estimated $1.7M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in DNLI in Q4 2020 and held it in 5 quarters. The position peaked at $3.45M in Q3 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 61,096 Denali Therapeutics shares in Q1 2023, an estimated $1.7M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Denali Therapeutics in Q4 2020 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Denali Therapeutics position peaked at $3.45M in Q3 2022.
202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.